News

Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and Management-09-02-2015
Volume11
Issue 9

CMC Biologics to Manufacture mAbs for the Treatment of Malaria

CMC Biologics will manufacture monoclonal antibodies (mAbs) and provide process development services for the PATH Malaria Vaccine Initiative.

 

CMC Biologics will manufacture monoclonal antibodies (mAbs) and provide process development services for the PATH Malaria Vaccine Initiative (MVI), CMC announced on Aug. 12, 2015. The company will use its proprietary production cell line for the project, and will test MVI’s investigational mAb for its ability to target circumsporozoite protein (CSP) and protect against infection by Plasmodium falciparum, the parasite that causes malaria.

"We will deliver cGMP material for MVI's preclinical and Phase I/II clinical studies in a remarkable 12 months-the fastest development timeline in the industry from DNA to delivery," Gustavo Mahler, PhD, global chief operations officer at CMC Biologics said in a press release.

Based on the success of the project with MVI, the group may hire CMC to investigate additional mAbs that bind to alternate epitopes. "Assuming this initial study is successful, we will evaluate other antibodies targeting novel vaccine targets for their capacity to protect humans from infection and therefore, inform future vaccine development efforts," confirmed Ashley J. Birkett, PhD, director at MVI.

Source: CMC Biologics

 

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content